Daly James M 4

What Happened
James M. Daly, a director of ACADIA Pharmaceuticals (ACAD), had restricted stock units (RSUs) vest and reported a derivative exercise/conversion on May 29, 2026. The filing shows two award acquisitions (16,004 and 9,311 RSUs; total 25,315 RSUs) reported at $0.00 and a derivative exercise/conversion of 8,107 shares (acquired) with a corresponding disposition of 8,107 derivative shares reported at $0.00. The RSUs vested on May 29, 2026 (the date of the annual meeting) and the filing reports no cash proceeds.

Key Details

• Transaction date: May 29, 2026; Form 4 filed June 1, 2026 (timely within required period).
• Reported transactions: Exercise/conversion (code M) — 8,107 derivative shares acquired; matching disposition of 8,107 derivative shares @ $0.00. Awards/grants (code A) — 16,004 RSUs and 9,311 RSUs acquired @ $0.00.
• Total RSUs vested: 25,315. Reported prices/values: $0.00 for awards and $0.00 for the reported disposition; one acquisition shows N/A for price.
• Shares owned after the reported transactions: not specified in the supplied filing data.
• Relevant footnotes: F1—each RSU equals a contingent right to one share; F2—those RSUs vested in full on May 29, 2026; F3—stock options (if any) vest quarterly over one year; F4—the reporting person elected to defer receipt of the underlying common shares for the RSUs until specified triggers (including up to five years).

Context

• "M" indicates an exercise or conversion of a derivative (e.g., option conversion). The filing shows an acquisition and an immediate disposition of 8,107 derivative shares at $0.00; the Form 4 does not report cash proceeds or further details about the nature of the disposition.
• RSU awards reported at $0.00 are typical (they are compensation awards that convert to shares); here the director has elected to defer receipt of the shares under the company plan until certain events.
• These entries are awards/vesting and a derivative conversion rather than an open-market purchase or sale; awards/vests are informative about compensation and holdings but do not by themselves indicate the director’s intent to buy or sell on the market.